Samsung Biologics opens tender to buy PolyPeptide at CHF 44.31 per share

Source Summary

20.07.2026 - Samsung Biologics moves to acquire PolyPeptide Group in a CHF 1.46bn all‐cash deal, offering a hefty premium and aiming to close by late 2026 amid strong H1 results.